文献速递流行病学与生物统计真实世界研究与卫生经济组学、生物样本库与精准医学

多基因风险定制的前列腺癌筛查:获益-危害与成本效果建模研究

Polygenic risk-tailored screening for prostate cancer: A benefit-harm and cost-effectiveness modelling study.
PubMed 文献 · PLoS Med · 2019-12-20

结果显示年龄筛查预防死亡最多但过度诊断达94,831例且成本效果最差;10年绝对风险4%阈值的风险定制筛查过度诊断减少三分之一、死亡预防仅少6.3%,在支付阈值£20,000-£30,000/QALY下具有成本效果的概率为48.4%-57.4%。

要点

  • 年龄筛查预防死亡最多但过度诊断94,831例,成本效果最差。
  • 10年绝对风险4%阈值的风险定制筛查过度诊断减少三分之一,死亡预防仅少6.3%。
  • 风险定制筛查在£20,000-£30,000/QALY支付阈值下具有成本效果的概率为48.4%-57.4%。

核心结论

  • 基于建模结果,向较高风险男性提供筛查可能减少过度诊断并改善获益-危害平衡和成本效果。
  • 最佳阈值取决于社会对获益-危害平衡和成本效果的判断。

研究设计与样本

  • 比较不筛查、年龄筛查(55-69岁每四年PSA检测)和风险定制筛查(10年绝对风险超阈值者从达阈值年龄起每四年PSA检测)。
  • 从卫生服务视角分析,包括风险评价、筛查、诊断和治疗直接成本。
  • 采用概率敏感性分析处理参数不确定性,未来成本与获益按每年3.5%贴现。

主要发现

  • 35年随访中,年龄筛查预防前列腺癌死亡最多(39,272,95% UI:16,792-59,685),但过度诊断94,831(95% UI:84,827-105,630)例。
  • 年龄筛查是研究中成本效果最差的策略。
  • 风险定制筛查在10年绝对风险4%阈值时产生最多QALYs,过度诊断64,384(95% UI:57,382-72,050)例,较年龄筛查减少三分之一,但预防死亡9,695(95% UI:2,853-15,851)例,少6.3%。
  • 相对不筛查,4%阈值风险定制筛查在支付阈值£20,000(US$26,000)/QALY和£30,000($39,386)/QALY下具有成本效果的概率分别为48.4%和57.4%。
  • 风险定制筛查的成本效果随阈值升高而改善。

关键数值与推荐

  • 风险阈值基于年龄和多基因谱。
  • 年龄筛查:55-69岁每四年PSA检测。
  • 风险定制筛查:55-69岁男性10年绝对风险大于阈值者,从达到阈值年龄起每四年PSA检测。

临床怎么用

  • 可为55-69岁男性基于年龄和多基因风险计算10年绝对风险,据此个体化决定是否筛查。
  • 考虑以10年绝对风险4%作为风险定制筛查的参考阈值之一,但需结合社会对获益-危害和成本效果的判断。

局限性

  • 模型基于队列结构,输入参数存在不确定性,结果需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The United States Preventive Services Task Force supports individualised decision-making for prostate-specific antigen (PSA)-based screening in men aged 55-69. Knowing how the potential benefits and harms of screening vary by an individual's risk of developing prostate cancer could inform decision-making about screening at both an individual and population level. This modelling study examined the benefit-harm tradeoffs and the cost-effectiveness of a risk-tailored screening programme compared to age-based and no screening. METHODS AND FINDINGS: A life-table model, projecting age-specific prostate cancer incidence and mortality, was developed of a hypothetical cohort of 4.48 million men in England aged 55 to 69 years with follow-up to age 90. Risk thresholds were based on age and polygenic profile. We compared no screening, age-based screening (quadrennial PSA testing from 55 to 69), and risk-tailored screening (men aged 55 to 69 years with a 10-year absolute risk greater than a threshold receive quadrennial PSA testing from the age they reach the risk threshold). The analysis was undertaken from the health service perspective, including direct costs borne by the health system for risk assessment, screening, diagnosis, and treatment. We used probabilistic sensitivity analyses to account for parameter uncertainty and discounted future costs and benefits at 3.5% per year. Our analysis should be considered cautiously in light of limitations related to our model's cohort-based structure and the uncertainty of input parameters in mathematical models. Compared to no screening over 35 years follow-up, age-based screening prevented the most deaths from prostate cancer (39,272, 95% uncertainty interval [UI]: 16,792-59,685) at the expense of 94,831 (95% UI: 84,827-105,630) overdiagnosed cancers. Age-based screening was the least cost-effective strategy studied. The greatest number of quality-adjusted life-years (QALYs) was generated by risk-based screening at a 10-year absolute risk threshold of 4%. At this threshold, risk-based screening led to one-third fewer overdiagnosed cancers (64,384, 95% UI: 57,382-72,050) but averted 6.3% fewer (9,695, 95% UI: 2,853-15,851) deaths from prostate cancer by comparison with age-based screening. Relative to no screening, risk-based screening at a 4% 10-year absolute risk threshold was cost-effective in 48.4% and 57.4% of the simulations at willingness-to-pay thresholds of GBP£20,000 (US$26,000) and £30,000 ($39,386) per QALY, respectively. The cost-effectiveness of risk-tailored screening improved as the threshold rose. CONCLUSIONS: Based on the results of this modelling study, offering screening to men at higher risk could potentially reduce overdiagnosis and improve the benefit-harm tradeoff and the cost-effectiveness of a prostate cancer screening program. The optimal threshold will depend on societal judgements of the appropriate balance of benefits-harms and cost-effectiveness.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Callender T, Emberton M, Morris S, et al. Polygenic risk-tailored screening for prostate cancer: A benefit-harm and cost-effectiveness modelling study. PLoS Med. 2019. PMID: 31860675. doi:10.1371/journal.pmed.1002998

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。